10 Best Biotech Penny Stocks to Buy According to Analysts
On December 24, Jared Holz of Mizuho joined 'Power Lunch' on CNBC to talk about how to play biotech moving into 2026.
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | MHR Fund Management Mark Rachesky | 28,967,103 | $62,858,614 | 6.16% | |
| 2. | Invenomic Capital Management Ali Motamed | 10,541,608 | $22,875,289 | +28% | 1.11% |
| 3. | Long Focus Capital Management John B. Helmers | 9,116,507 | $19,782,820 | -23% | 0.65% |
| 4. | Palo Alto Investors William Leland Edwards | 7,618,132 | $16,531,346 | +123% | 3.06% |
| 5. | Millennium Management Israel Englander | 4,413,451 | $9,577,189 | -53% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.84 | 30,000 | $55,200.00 | 30,000 | 2025-06-05 | Filing | |
| $1.74 | 5,600 | $9,743.44 | 206,852 | 2025-05-23 | Filing | |
| $1.69 | 25,000 | $42,250.00 | 374,646 | 2025-05-14 | Filing | |
| $9.15 | 250,000 | $2,287,500.00 | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | $292,800.00 | 54,000 | 2024-02-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.06 | 50,000 | $503,000.00 | 7,500 | 2024-11-12 | Filing | |
| $8.71 | 20,500 | $178,612.40 | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | $304,799.75 | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | $491,740.20 | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | $117,645.00 | 154,000 | 2015-09-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 25,956,289 | $56,325,148 | 0% | |
| 2. | 24,058,983 | $52,207,993 | 0% | |
| 3. | 13,309,959 | $28,882,611 | 0% | |
| 4. | 6,868,303 | $14,905,575 | 0% | |
| 5. | 6,575,502 | $14,268,839 | 0% |
News See All
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2025 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q3 2025 Earnings Call Transcript November 6, 2025Iovance Biotherapeutics, Inc. beats earnings expectations.
Iovance Biotherapeutics, Inc. (IOVA) Targeting $1B on Amtagvi Sales amid Cost Cuts
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the best healthcare penny stocks to buy now. On September 9, at the H.C.
11 Best Healthcare Penny Stocks to Buy Now
The US healthcare sector is one of the biggest in the world, with spending expected to reach $5.3 trillion this year.
Top 10 Stocks Under $10 That Could Triple
The Bureau of Labor Statistics reported that only 22,000 jobs were added in August, much less than the 75,000 jobs that economists polled by Dow Jones had expected.
Artisan Small Cap Fund Exited Its Stake in Iovance Biotherapeutics (IOVA) Due to Operational Challenges
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Iovance Biotherapeutics (IOVA) Receives Conditional Approval From Health Canada
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Most Oversold Penny Stocks to Buy Now. On August 18, Iovance Biotherapeutics, Inc.
11 Most Oversold Penny Stocks to Buy Now
On August 20, Venu Krishna, the head of US equity strategy at Barclays, joined CNBC television to discuss the probable market response to the Federal Reserve's policy signals, particularly in light of...
Wells Fargo Lowers Iovance Biotherapeutics (IOVA) PT to $14 Despite Strong Amtagvi Sales, Q2 Revenue Growth
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is one of the most promising penny stocks under $5.
13 Most Promising Penny Stocks Under $5
On August 12, Jill Carey Hall, BofA Securities head of US small and mid-cap strategy, joined 'The Exchange' on CNBC to discuss the outlook for small caps, amidst their underperformance.